Key result
Intravenous ferric carboxymaltose improves symptoms and exercise capacity in heart failure patients with iron deficiency, a comorbidity affecting up to 50-80% of this population.
Why the study?
Does intravenous ferric carboxymaltose improve symptoms, exercise capacity, and quality of life in heart failure patients with iron deficiency?
Population
Heart failure patients with iron deficiency
Design
Review
Authors
Loading...
May support ESC recommendations for symptom relief; leaves open outcome trials in iron-deficient HF.
Does intravenous ferric carboxymaltose improve symptoms, exercise capacity, and quality of life in heart failure patients with iron deficiency?
Intravenous ferric carboxymaltose is an effective treatment for improving symptoms and reducing hospitalizations in heart failure patients with iron deficiency, supporting ESC guideline recommendations.
Katrina Mountfort (2015) conducted a review in Heart failure with iron deficiency. Intravenous ferric carboxymaltose was evaluated. Intravenous ferric carboxymaltose improves symptoms and exercise capacity in heart failure patients with iron deficiency, a comorbidity affecting up to 50-80% of this population.